Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 3/20 | 0.55 |
| ▸ | METAP1 | P53582 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575927 | 0.90 | EPHX2 (0.64) | EPHX2SSTR4LMNAGAAHDAC3 | |
| SCHEMBL14025088 | 0.86 | EPHX2 (0.60) | EPHX2SSTR4LMNAGAAMETAP2 | |
| SCHEMBL14004671 | 0.86 | EPHX2 (0.60) | EPHX2SSTR4LMNAGAAHDAC3 | |
| SCHEMBL16480210 | 0.86 | EPHX2 (0.60) | EPHX2SSTR4LMNAGAAHDAC3 | |
| SCHEMBL5520593 | 0.84 | ALDH1A1 (0.63) | EPHX2SSTR4LMNAGAAMETAP2 | |
| SCHEMBL29825391 | 0.84 | ALDH1A1 (0.63) | EPHX2SSTR4LMNAGAAMETAP2 | |
| SCHEMBL12943904 | 0.84 | ALDH1A1 (0.63) | EPHX2SSTR4LMNAGAAMETAP2 | |
| SCHEMBL12906742 | 0.84 | ALDH1A1 (0.63) | EPHX2SSTR4LMNAGAAMETAP2 | |
| SCHEMBL8518963 | 0.82 | LMNA (0.61) | EPHX2SSTR4LMNAGAAMETAP2 | |
| SCHEMBL7263715 | 0.82 | LMNA (0.61) | EPHX2SSTR4LMNAGAAMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11452712-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20180161309-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ARCA BIOPHARMA, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9763916-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170000766-A1 | Methods and Compositions Involving (S)-Bucindolol | GENVARA BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9446023-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150190375-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | GENVARA BIOPHARMA, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8946284-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120108617-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ARCA BIOPHARMA, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161309-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ADRB3, ADRB2, ADRB1 | EPHX2 522/4885SSTR4 2294/4885LMNA 2234/4885 |
| US-20150190375-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ADRB3, ADRB2, ADRB1 | EPHX2 522/4885SSTR4 2294/4885LMNA 2234/4885 |
| US-20120108617-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ADRB2, ADRB3, ADRB1 | EPHX2 523/4885SSTR4 2172/4885LMNA 2490/4885 |
| US-11452712-B2 | Methods and compositions involving (S)-bucindolol | ADRB3, ADRB2, ADRB1 | EPHX2 522/4885SSTR4 2294/4885LMNA 2234/4885 |
| US-20170000766-A1 | Methods and Compositions Involving (S)-Bucindolol | ADRB3, ADRB2, ADRB1 | EPHX2 522/4885SSTR4 2294/4885LMNA 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.